TLK protein inhibition activates the innate immune system

These proteins are a potential therapeutic target for enhancing the effect of some cancer treatments.Inhibition of TLK proteins triggers the Alternative Lengthening of Telomeres pathway, a common process in some of the most aggressive types of cancer, such as glioblastoma. The study, performed by the Genomic Instability and Cancer Laboratory at IRB Barcelona, has been published in the journal Cell Reports.